We are to be a globally respected scientific leader in healthcare solutions development.
After becoming a global R&D center, our projects in China have grown 50% annually. By syncing up with the global pipeline, key projects have achieved 100% growth, with early-stage R&D projects accounting for 20% of this growth. AstraZeneca R&D China has shifted focus to support earlier stage research compared to the more traditional confirmatory studies, and new drug launches. We are now leading in certain high-prevalence disease areas in China.’ A summary of the recent developments by Dr. He Jing, Global Senior VP & President of R&D China.
As a crucial member of AstraZeneca’s Global R&D Network, we continuously work with the ‘In China, with China, for Global’ philosophy to enhance local R&D capabilities. Currently, the R&D China team consists of more than 900 people, covering oncology, respiratory & immunology, vaccines & immune therapies, cardiovascular, renal & metabolism, and rare diseases. With over 180 projects in our R&D pipeline, which cover the entire clinical development process ranging from translational medicine to Phase III clinical trials.
AstraZeneca, recognized as a 'China Top Employer' for 14 years, is committed to supporting talent development. At R&D China, we push for the unconventional, foster creativity, and inspire motivation. Your personal growth and development will help us realize our common vision.
